Clinical Trial Detail

NCT ID NCT01375842
Title A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Atezolizumab

Age Groups: adult

No variant requirements are available.